Archeus Technologies

WI - MadisonPharmaceutical5 H-1B visas (FY2023)

Focus: Archeus Technologies is a radiopharmaceutical company focused on oncology, headquartered in Madison, Wisconsin. The company is in early-stage development with a single Phase 1 program.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Archeus Technologies

AI assessmentNot Hiring

No open roles listed right now. Follow Archeus Technologies to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

90Y-NM600

Metastatic Cancer

Phase 1

Clinical Trials (1)

NCT07197671Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer

Phase 1

Help build intelligence for Archeus Technologies

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Specialized focus on radiopharmaceuticals, an emerging and differentiated modality with high clinical and commercial potential in oncology
Ground-floor opportunity at a pre-revenue biotech with potential for significant equity upside if pipeline advances
Access to cutting-edge nuclear medicine technology in a therapeutic area with limited competition

Watch Out For

Extremely early stage with only 1 Phase 1 trial, meaning many years before any meaningful clinical validation or revenue generation
No current hiring (0 active job openings), suggesting tight headcount or early-stage operations that may limit near-term career mobility
Minimal public information on funding, financials, and company size creates uncertainty around runway and stability

Generated by Claude from Archeus Technologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

yttrium Y-90 NM600

Metastatic Cancer

Phase 1

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 1 clinical trial

Top TAs: Oncology

H-1B (2023): 5 approvals

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

83%

Rate

Source: USCIS H-1B Employer Data Hub